2002
DOI: 10.1152/ajprenal.00032.2002
|View full text |Cite
|
Sign up to set email alerts
|

Plasminogen activator inhibitor-1 and the kidney

Abstract: Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor that was isolated 20 years ago. First recognized as an inhibitor of intravascular fibrinolysis, it is now evident that PAI-1 is a multifunctional protein with actions that may be dependent on or independent of its protease inhibitory effects. The latter often involve interactions between PAI-1 and vitronectin or the urokinase receptor. The protease-inhibitory actions of PAI-1 extend beyond fibrinolysis and include extracellular matrix tur… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
134
1
6

Year Published

2003
2003
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 174 publications
(145 citation statements)
references
References 180 publications
4
134
1
6
Order By: Relevance
“…As reported previously (37,38), HKC cells constitutively express plasminogen as well as other components of PA/plasmin axis. However, plasmin activity was found to be very low in the absence of exogenous plasminogen ( Figure 3F).…”
Section: Discussionsupporting
confidence: 73%
“…As reported previously (37,38), HKC cells constitutively express plasminogen as well as other components of PA/plasmin axis. However, plasmin activity was found to be very low in the absence of exogenous plasminogen ( Figure 3F).…”
Section: Discussionsupporting
confidence: 73%
“…It plays a role in wound healing through its effects on keratinocyte cell migration (62). It is a factor promoting glomerulosclerosis and tubulointerstitial fibrosis making it an important candidate in diabetic nephropathy (63). It is necessary for peripheral nerve regeneration establishing a link to peripheral neuropathy (64).…”
Section: Discussionmentioning
confidence: 99%
“…PAI-1, a primary physiological inhibitor of plasminogen activators (uPA and tPA), inhibits both fibrinolysis and proteolysis and plays an important role in mediating the cardiovascular complications associated with T2DM such as nephropathy (10), retinopathy (11), coronary artery disorders (12), and hypertension (13). Consequently, it is believed that normalizing plasma PAI-1 levels will retard the progression of cardiovascular complications (14).…”
mentioning
confidence: 99%